Psychosocial and neurocognitive functioning in unipolar and bipolar depression: A 12-month prospective study

Godard, Julie; Baruch, Philippe; Grondin, Simon; Lafleur, Martin F.

doi:10.1016/j.psychres.2011.09.013

Cited by 77 publications

(59 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…McIntyre et al [37] Narrative review Three identified studies were relevant; see findings for Buist-Bouwman et al [40], Jaeger et al [41], and Godard et al [44] in Table 1 Cognitive dysfunction mediates psychosocial impairment in MDD, particularly with regard to workplace performance…”

Section: Main Conclusionmentioning

confidence: 99%

Cognitive dysfunction and work productivity in major depressive disorder

Clark

DiBenedetti

Pérez

2016

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Given the prevalence of cognitive dysfunction, and the humanistic and economic impact of occupational impairments in individuals with MDD, the relationship between cognitive dysfunction in MDD and work-related outcomes requires characterization. A selective review of the literature was conducted to better understand and further highlight this relationship. Expert commentary: Although current evidence is limited, MDD-related cognitive dysfunction may have a direct negative impact on work productivity. Presenteeism is the key outcome impacted by cognitive deficits in MDD. Additional well-designed prospective observational research may clarify how cognitive dysfunction influences the MDD-work productivity relationship. Use of reliable, valid, and sensitive measures of cognitive functioning and work productivity in MDD is warranted.

show abstract

Section: Main Conclusionmentioning

confidence: 99%

Cognitive dysfunction and work productivity in major depressive disorder

Clark

DiBenedetti

Pérez

2016

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…In contradistinction to research in schizophrenia, bipolar disorder, autism, and other lifelong disorders, the association between cognitive dysfunction in MDD and psychosocial outcomes has not been as extensively studied [34,35]. Moreover, available studies have significant methodological limitations.…”

Section: Relationship Between Cognitive Dysfunction and Health Outcommentioning

confidence: 99%

The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder

et al. 2015

View full text Add to dashboard Cite

Insufficient outcomes amongst adults with major depressive disorder (MDD) provide the impetus to identify and refine therapeutic targets that are most critical to outcome from patient, provider, and societal perspectives. Towards this aim, a pivotal shift towards the transnosological domain, cognition, is occurring in the study of MDD and other brain disorders. This paper aims to provide a framework for conceptualizing and prioritizing cognitive function amongst adults with MDD with a particular view to provide a conceptual framework for research and clinical priorities. We also summarize extant data pertaining to psychotropic effects, notably antidepressants, on the cognitive dimension/domain. This narrative review was based on articles identified through a PubMed/MEDLINE search of all English-language articles published between January 1966 and October 2014. The search words were major depressive disorder, depression, unipolar depression, cognition, cognitive dysfunction, cognitive deficit, and cognitive function. The search was supplemented with a manual review of relevant references. The selection of articles for inclusion in this review was based on overall methodological quality as well as on their pertinence to informing the framework described herein. Cognitive dysfunction in MDD is a discrete domain subserved by discrete yet overlapping substrates. There is a need to provide a glossary of terms commonly employed in the cognition literature for consensus as to the appropriate screening, measurement, and monitoring tools. The guiding principle of measurement-based care should include systematic assessment and measurement of cognition in subpopulations with MDD, as a tactic to improve outcome. Relatively few treatment strategies have demonstrated efficacy specifically for the cognitive domain in MDD. The antidepressant vortioxetine has replicated evidence of specific pro-cognitive effects in adults with MDD across multiple subdomains of cognitive function. Vortioxetine is a novel antidepressant that is hypothesized to act through a combination of direct effects on receptor activity and serotonin receptor inhibition, as well as other systems. Pro-cognitive effects for other US FDA-approved agents are suggested, but pseudospecificity has not been excluded as a possible explanation of their beneficial effects on cognitive function. A disparate assortment of other agents are currently under investigation for possible benefit in mitigating cognitive deficits and improving cognitive performance (e.g., intranasal insulin, erythropoietin, anti-inflammatory agents). Non-pharmacological approaches including, but not limited to, cognitive remediation (CR), aerobic exercise, and neuromodulation are promising.

show abstract

“…Particularly, executive function, working memory, attention, and psychomotor processing were associated with diminished productivity as whole (Lee et al, 2012;Trivedi et al, 2013). Therefore, addressing cognitive dysfunction may have vital therapeutic implication in the workplace (Baune et al, 2010;Godard et al, 2012), since performance variability seemed to be better explained by cognitive functioning than severity of depression symptoms (McIntyre et al, 2013(McIntyre et al, , 2015Papakostas, 2014;Trivedi and Greer, 2014).…”

Section: Discussionmentioning

confidence: 99%